The first cancer drug with no meaningful adverse effects.
We are a Swiss company founded 2019 in Zug, with a patented method to reverse carcinogenesis. Operations starting in NYC and Florida with local investors.
In preclinical trials, CRB091 worked against deadly cancers, such as colorectal cancer, pancreatic cancer, and triple-negative breast cancer. It was shown to reduce side effects of chemotherapy, and add to its efficacy. Entering patients in 2 years after extensive regulatory processes, for which we seek funding, first step 500k Euros as a SAFE note, total need 5M to first in-human permission.
Unique innovation:
CRB091 affects cancer where it really comes from, the metabolic failures, restoring mitochondrial functions.
De-risked: the drug candidate CRB091 is a combination of non-toxic efficacious active ingredients, and therefore, we have been able to establish both efficacy AND safety already at this stage. A fast track leads to patients in just two years.
The team is lean, and consists of experienced leaders in life science, finance, and top scientists. An extensive network of advisors, all professor level, have helped develop the drug candidate. There is a dramatic value increase ahead going to human.
Available to discuss the very rational science and plans anytime!
Ready to Ask For Funding for your company?
Post a Funding Request